What is the Purpose of this Study?
This study focuses on individuals who have recently been diagnosed with glioblastoma (GB), a type of brain cancer. The purpose of the study is to evaluate the safety and effectiveness of BPM31510 (an experimental drug) and vitamin K1 in treating and slowing down the progression of GB, when combined with standard radiation therapy and temozolomide (a type of chemotherapy). Researchers also aim to assess the tolerability (whether side effects can be handled) of BPM31510 and Vitamin K1. Participants will receive the treatment of BPM31510 and vitamin K1 (combined with standard radiation therapy and temozolomide) for 8 weeks. A catheter (tube) will be used to administer BPM31510. The combination of BPM31510 and vitamin K1 with radiation therapy and temozolomide is experimental.
Eligibility
- 1. Subjects with newly diagnosed pathologically verified GB.
- 2. No prior RT, chemotherapy, immunotherapy, or targeted agents administered specifically for the lesion being treated.
- 3. Age ≥18 y.
- 4. Life expectancy ≥3 months.
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center : Shannon Cyhan
More about this Clinical Trial
What is the full name of this clinical trial?
BPM31510IV-11: A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma